Sevabertinib
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC).
Journal: International journal of molecular sciences
Published: April 08, 2026
Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. Reply.
Journal: The New England journal of medicine
Published: March 26, 2026
Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: March 26, 2026
Class-level DILI saturation and hERG-driven risk stratification among 2024-2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis.
Journal: Investigational new drugs
Published: March 16, 2026
Acquired ERBB2 Amplification and Overexpression as On-Target Resistance Mechanisms to Zongertinib With Subsequent Response to Trastuzumab-Deruxtecan: A Case Report.
Journal: JTO clinical and research reports
Published: March 09, 2026
Oral TKI sevabertinib approved for advanced HER2-mutant NSCLC.
Journal: Cancer
Published: March 04, 2026
HER2-ADC and HER2-TKI Overcomes HER2 Amplification as an Acquired Resistance to Zongertinib - A Case Report.
Journal: Lung Cancer (Auckland, N.Z.)
Published: February 09, 2026
Sevabertinib (Hyrnuo) for NSCLC.
Journal: The Medical letter on drugs and therapeutics
Published: February 06, 2026
HER2 Alterations in Non-Small Cell Lung Cancer: Emerging Perspectives on the Therapeutic Landscape.
Journal: International journal of molecular sciences
Published: January 28, 2026
Synthesis and Clinical Application of Small-Molecule Drugs Approved by FDA in 2025.
Journal: Medicinal research reviews
Published: December 31, 2025
Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review.
Journal: Targeted oncology
Published: December 19, 2025
Last Updated: 06/30/2026